Report #2833384

Received Mar 27, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: Age unknown
State: —
Recovered: Recovered
Vaccinated: Feb 28, 2025
Onset: Mar 1, 2025
Days to onset: 1
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
RVX	ROTAVIRUS (NO BRAND NAME)	UNKNOWN MANUFACTURER	UNK	UNK	—

Symptoms (1)

Genital herpes

Symptom narrative

Activated genital Herpes; This non-serious case was reported by a consumer and described the occurrence of genital herpes in a 77-year-old male patient who received RSVPreF3 adjuvanted (RSV vaccine) for prophylaxis. On 28-FEB-2025, the patient received RSV vaccine. On 01-MAR-2025, 1 days after receiving RSV vaccine, the patient experienced genital herpes (Verbatim: Activated genital Herpes). The patient was treated with docosanol (Abreva). On 15-MAR-2025, the outcome of the genital herpes was resolved (duration 14 days). It was unknown if the reporter considered the genital herpes to be related to RSV vaccine. It was unknown if the company considered the genital herpes to be related to RSV vaccine. Additional Information: GSK Receipt Date: 17-MAR-2025 The patient self-reported this case. The patient stated that he applied Abreva twice daily, until the outbreak dried up and started healing. The patient had activated genital herpes and the symptoms were treated.